211 related articles for article (PubMed ID: 32580506)
1. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
[TBL] [Abstract][Full Text] [Related]
4. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
5. Leukotriene A4 hydrolase as a target for cancer prevention and therapy.
Chen X; Wang S; Wu N; Yang CS
Curr Cancer Drug Targets; 2004 May; 4(3):267-83. PubMed ID: 15134534
[TBL] [Abstract][Full Text] [Related]
6. The development of novel LTA
Low CM; Akthar S; Patel DF; Löser S; Wong CT; Jackson PL; Blalock JE; Hare SA; Lloyd CM; Snelgrove RJ
Sci Rep; 2017 Mar; 7():44449. PubMed ID: 28303931
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, docking, cytotoxicity, and LTA
El-Naggar MH; Mira A; Abdel Bar FM; Shimizu K; Amer MM; Badria FA
Bioorg Med Chem; 2017 Feb; 25(3):1277-1285. PubMed ID: 28065501
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2011 May; 46(5):1593-603. PubMed ID: 21377770
[TBL] [Abstract][Full Text] [Related]
9. Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor.
Stsiapanava A; Olsson U; Wan M; Kleinschmidt T; Rutishauser D; Zubarev RA; Samuelsson B; Rinaldo-Matthis A; Haeggström JZ
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4227-32. PubMed ID: 24591641
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design.
Thangapandian S; John S; Arooj M; Lee KW
PLoS One; 2012; 7(4):e34593. PubMed ID: 22496831
[TBL] [Abstract][Full Text] [Related]
11. Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors.
Röhn TA; Numao S; Otto H; Loesche C; Thoma G
Expert Opin Drug Discov; 2021 Dec; 16(12):1483-1495. PubMed ID: 34191664
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking and pharmacophore filtering in the discovery of dual-inhibitors for human leukotriene A4 hydrolase and leukotriene C4 synthase.
Thangapandian S; John S; Sakkiah S; Lee KW
J Chem Inf Model; 2011 Jan; 51(1):33-44. PubMed ID: 21133343
[TBL] [Abstract][Full Text] [Related]
13. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase.
Fourie AM
Curr Opin Investig Drugs; 2009 Nov; 10(11):1173-82. PubMed ID: 19876785
[TBL] [Abstract][Full Text] [Related]
14. Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods.
Qin R; Wang H; Yan A
SAR QSAR Environ Res; 2021 May; 32(5):411-431. PubMed ID: 33896285
[TBL] [Abstract][Full Text] [Related]
15. Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A
Markert C; Thoma G; Srinivas H; Bollbuck B; Lüönd RM; Miltz W; Wälchli R; Wolf R; Hinrichs J; Bergsdorf C; Azzaoui K; Penno CA; Klein K; Wack N; Jäger P; Hasler F; Beerli C; Loetscher P; Dawson J; Wieczorek G; Numao S; Littlewood-Evans A; Röhn TA
J Med Chem; 2021 Feb; 64(4):1889-1903. PubMed ID: 33592148
[TBL] [Abstract][Full Text] [Related]
16. A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.
Poras H; Duquesnoy S; Fournié-Zaluski MC; Ratinaud-Giraud C; Roques BP; Ouimet T
Anal Biochem; 2013 Oct; 441(2):152-61. PubMed ID: 23851339
[TBL] [Abstract][Full Text] [Related]
17. Thermodynamic properties of leukotriene A
Wittmann SK; Kalinowsky L; Kramer JS; Bloecher R; Knapp S; Steinhilber D; Pogoryelov D; Proschak E; Heering J
Bioorg Med Chem; 2016 Nov; 24(21):5243-5248. PubMed ID: 27651294
[TBL] [Abstract][Full Text] [Related]
18. Capturing LTA
Stsiapanava A; Samuelsson B; Haeggström JZ
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9689-9694. PubMed ID: 28827365
[TBL] [Abstract][Full Text] [Related]
19. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin.
Chen X; Li N; Wang S; Wu N; Hong J; Jiao X; Krasna MJ; Beer DG; Yang CS
J Natl Cancer Inst; 2003 Jul; 95(14):1053-61. PubMed ID: 12865451
[TBL] [Abstract][Full Text] [Related]
20. In silico modeling of the molecular structure and binding of leukotriene A4 into leukotriene A4 hydrolase.
Paz PB; Vega-Hissi EG; Estrada MR; Garro Martinez JC
Chem Biol Drug Des; 2012 Dec; 80(6):902-8. PubMed ID: 22913921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
